{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:47:27Z","timestamp":1772758047264,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Government and School Cooperation Program of Nanchong, Sichuan, China","award":["19SXHZ0148"],"award-info":[{"award-number":["19SXHZ0148"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of intravenous immunoglobulin (IVIG) in the treatment of dermatomyositis (DM) and polymyositis (PM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched PubMed, Embase, and the China National Knowledge Infrastructure for relevant studies from July 1919 to May 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventeen papers pertinent to our questions were found: In a meta-analysis, we found that IVIG significantly improved the level of CK (SMD (STD. Mean Difference)\u2009=\u2009\u22120.69; 95%CI \u22120.93, \u22120.46; P\u2009&amp;lt;\u20090.0001), Manual Muscle Test (SMD\u2009=\u20091.12; 95%CI 0.77, 1.47; P\u2009&amp;lt;\u20090.00001), Medical Research Council (SMD\u2009=\u20091.59; 95%CI 0.86, 2.33; P\u2009&amp;lt;\u20090.00001), Activities of Daily Living (SMD\u2009=\u20091.07; 95%CI 0.59, 1.56; P\u2009&amp;lt;\u20090.0001). The CK levels in DM and PM were also significantly improved after IVIG (SMD\u2009=\u2009\u22120.73; 95%CI \u22121.12, \u22120.34; P\u2009=\u20090.0002 and SMD\u2009=\u2009\u22123.29; 95%CI \u22125.82, \u22120.76; P\u2009&amp;lt;\u20090.0001, respectively). The meta-analysis of three RCTs showed that there was a statistically significant improvement after IVIG (SMD\u2009=\u20090.63; 95%CI 0.22, 1.03; P\u2009=\u20090.002). In a random effects model, pooled muscle power improvement rate was 77% (95% CI: 66.0\u201387.0%). Meta-analyses of IVIG as first-line therapy showed a significant improvement of the CK level (SMD\u2009=\u2009\u22120.71; 95%CI \u22121.12, \u22120.30; P\u2009=\u20090.0007). The polled improvement rate of oesophageal disorders was 88% (95% CI: 80.0\u201395.0%). There was no statistically significant difference in the rate of improvement between the number of courses &amp;lt;2 and \u22652 (0.80% vs. 0.80%, P\u2009=\u20090.9). The proportion of corticosteroid-sparing success reached 81.8%. Adverse reactions following IVIG administration are usually mild and transient. Seven patients developed serious adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>IVIG seems to be an effective drug for DM\/PM, improving muscle strength, CK levels, and oesophageal involvement, and it is well tolerated by patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac057","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T16:13:39Z","timestamp":1654359219000},"page":"533-542","source":"Crossref","is-referenced-by-count":7,"title":["The therapeutic efficacy and safety of intravenous immunoglobulin in dermatomyositis and polymyositis: A systematic review and meta-analysis"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-3738","authenticated-orcid":false,"given":"Anji","family":"Xiong","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiying","family":"Qiang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzi","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Shuai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huini","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qilang","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoyao","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shifeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxu","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiquan","family":"Shuai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College , Nanchong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Chengdu Medical College , Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"2023092217015091400_R1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11940-003-0025-9","article-title":"Dermatomyositis and polymyositis","volume":"5","author":"Briemberg","year":"2003","journal-title":"Curr Treat Options Neurol"},{"key":"2023092217015091400_R2","first-page":"351, 3","article-title":"Polymyositis","volume":"17","author":"Bradley","year":"1977","journal-title":"Br J Hosp Med"},{"key":"2023092217015091400_R3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00003495-199754010-00003","article-title":"Recognition and management of myositis","volume":"54","author":"Cherin","year":"1997","journal-title":"Drugs"},{"key":"2023092217015091400_R4","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"key":"2023092217015091400_R5","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1073\/pnas.89.8.3325","article-title":"Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain","volume":"89","author":"Marchalonis","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023092217015091400_R6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0140-6736(93)90563-V","article-title":"Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations","volume":"341","author":"Blasczyk","year":"1993","journal-title":"Lancet"},{"key":"2023092217015091400_R7","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"key":"2023092217015091400_R8","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.161.7.3781","article-title":"Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway","volume":"161","author":"Prasad","year":"1998","journal-title":"J Immunol"},{"key":"2023092217015091400_R9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","article-title":"Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis","volume":"9","author":"Danieli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"2023092217015091400_R10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.1987.03400040111034","article-title":"Reversal of chronic polymyositis following intravenous immune serum globulin therapy","volume":"258","author":"Roifman","year":"1987","journal-title":"Jama"},{"key":"2023092217015091400_R11","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"2023092217015091400_R12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2023092217015091400_R13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","article-title":"Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients","volume":"91","author":"Cherin","year":"1991","journal-title":"Am J Med"},{"key":"2023092217015091400_R14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","article-title":"Immunoglobulin therapy in inflammatory myopathies","volume":"65","author":"Mastaglia","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023092217015091400_R15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2023092217015091400_R16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3109\/s10165-003-0250-9","article-title":"Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis","volume":"13","author":"Hara","year":"2003","journal-title":"Mod Rheumatol"},{"key":"2023092217015091400_R17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/s10165-007-0013-0","article-title":"Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis","volume":"18","author":"Saito","year":"2008","journal-title":"Mod Rheumatol"},{"key":"2023092217015091400_R18","first-page":"397","article-title":"The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study","volume":"30","author":"Kampylafka","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2023092217015091400_R19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2018.1521185","article-title":"Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists","volume":"29","author":"Kohsaka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023092217015091400_R20","first-page":"588","article-title":"Efficacy and safety of the combined treatment with intravenous immunoglobulin and oral glucocorticoid in the elderly with dermatomyositis","volume":"27","author":"Tian","year":"2008","journal-title":"Chin J Geriatr"},{"key":"2023092217015091400_R21","first-page":"1092","article-title":"Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients","volume":"21","author":"Cherin","year":"1994","journal-title":"J Rheumatol"},{"key":"2023092217015091400_R22","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023092217015091400_R23","first-page":"29","article-title":"High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels","volume":"10","author":"Gottfried","year":"2000","journal-title":"Eur J Dermatol"},{"key":"2023092217015091400_R24","first-page":"456","article-title":"Dermatomyositis requires long-term treatment with combined immunosuppressive and immunoglobulin therapy","volume":"19","author":"Wiala","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"2023092217015091400_R25","article-title":"efficacy of intravenous immunoglobulin therapy in refractory dysphagia in patients with idiopathic inflammatory myopathies","volume":"76","author":"Giannini","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023092217015091400_R26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imj.13308","article-title":"Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients","volume":"47","author":"Foreman","year":"2017","journal-title":"Intern Med J"},{"key":"2023092217015091400_R27","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1097\/RHU.0000000000001418","article-title":"Intravenous immunoglobulin for inflammatory myositis: experience in a tertiary medical center","volume":"27","author":"Ohad","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"2023092217015091400_R28","author":"Surmachevska","year":"2022"},{"key":"2023092217015091400_R29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/art.1780280303","article-title":"Prognostic factors in polymyositis\/dermatomyositis. A computer-assisted analysis of ninety-two cases","volume":"28","author":"Benbassat","year":"1985","journal-title":"Arthritis Rheum"},{"key":"2023092217015091400_R30","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/archinte.1983.00350120052013","article-title":"The esophageal motility disorder of polymyositis. A prospective study","volume":"143","author":"Jacob","year":"1983","journal-title":"Arch Intern Med"},{"key":"2023092217015091400_R31","first-page":"1336","article-title":"Pulmonary involvement in polymyositis and in dermatomyositis","volume":"25","author":"Marie","year":"1998","journal-title":"J Rheumatol"},{"key":"2023092217015091400_R32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-199905000-00001","article-title":"Influence of age on characteristics of polymyositis and dermatomyositis in adults","volume":"78","author":"Marie","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"2023092217015091400_R33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00002281-199711000-00003","article-title":"Evaluation and treatment of speech and swallowing disorders associated with myopathies","volume":"9","author":"Sonies","year":"1997","journal-title":"Curr Opin Rheumatol"},{"key":"2023092217015091400_R34","first-page":"207","article-title":"Survival in polymyositis: corticosteroids and risk factors","volume":"4","author":"Carpenter","year":"1977","journal-title":"J Rheumatol"},{"key":"2023092217015091400_R35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(86)92511-0","article-title":"Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients","volume":"2","author":"Woodruff","year":"1986","journal-title":"Lancet"},{"key":"2023092217015091400_R36","article-title":"Cardiovascular events in adult polymyositis and dermatomyositis: a meta-analysis of observational studies","author":"Xiong","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023092217015091400_R37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","article-title":"Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"key":"2023092217015091400_R38","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1191\/0961203303lu2168rr","article-title":"Review: intravenous immunoglobulin therapy and thromboembolic complications","volume":"14","author":"Katz","year":"2005","journal-title":"Lupus"},{"key":"2023092217015091400_R39","article-title":"Decreased Serum 25-(OH)-D level associated with muscle enzyme and myositis specific autoantibodies in patients with idiopathic inflammatory myopathy","volume":"12","author":"Yu","year":"2021","journal-title":"Front Immunol"},{"key":"2023092217015091400_R40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/jth.12118","article-title":"25-Hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18,791 participants","volume":"11","author":"Brondum-Jacobsen","year":"2013","journal-title":"J Thromb Haemost"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac057\/44264270\/roac057.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/3\/533\/51715139\/roac057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/3\/533\/51715139\/roac057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T17:32:47Z","timestamp":1695403967000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/3\/533\/6602025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,4]]},"published-print":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac057","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,6,4]]}}}